AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01856257 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: belatacept
Description: Participants will receive belatacept at a dose of 10mg/kg up on day 1, 5, 14, 28, 56 and 84. After 84 days, subjects will receive a maintenance dose of 5 mg/kg every 4 weeks until completion of the trial.
Study NCT01856257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylprednisolone
Description: Methylprednisolone will be administered at a target dose of 500 mg beginning on the day of transplant, and tapered to 250 mg day 1 post-transplant, 125 mg day 2 post-transplant, 60 mg day 3 post-transplant, 30 mg day 4 post-transplant and day 5 post-transplant 0 mg if therapeutic tacrolimus level achieved for groups 1 and 3.
Study NCT01856257 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methylprednisolone
Description: Methylprednisolone will be administered at a target dose of 500 mg beginning on the day of transplant, and tapered to 250 mg day 1 post-transplant, 125 mg day 2 post-transplant, 60 mg day 3 post-transplant, 30 mg day 4 post-transplant and day 5 post-transplant 0 mg if therapeutic tacrolimus level achieved for groups 1 and 3.
Study NCT03781908 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Silver Nitrate
Description: First, pleural fluid drainage will be done after administration of 5 cc of local anesthetic lidocain1% either by insertion of chest tube (26F or 28F ) or by using ultrasonography. Pleural fluid drainage will be terminated when the patient want to cough to make sure that the pleural cavity is empty, then the sclerosant material will be injected, patients will receive 0.5% silver nitrate diluted in 50 ml distilled water with 10 ml of local anaesthetic lidocaine 1%.
Study NCT03781908 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Indwelling Pleural Catheter
Description: First , insert the wire into the pleural effusion at approximately the anterior axillary line. A 1-2 cm incision is made over the wire. A chest wall tunnel (5-8 cm in length) is created with a counter incision. The catheter is pulled through the tunnel and out next to the wire. After dilation of the wire tract with a Teflon peel-away sheath, the indwelling catheter is inserted into the chest. The counter incision is closed primarily, and the catheter is secured to the skin medially with a suture.
Study NCT01856257 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: basiliximab
Description: Basiliximab will be administered in two doses of 20 mg each.
Study NCT01856257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil
Description: Mycophenolate Mofetil will be administered at a target dose of 1000 mg orally twice a day. Myfortic® (mycophenolate sodium) may be used as a replacement for MMF. Mycophenolate sodium will be dosed at 720 mg PO BID. Mycophenolate sodium will be adjusted based on clinical complications.
Study NCT01044810 — intervention group
Intervention type: DRUG
Intervention: Efavirenz-based regimens
Description: Efavienz: 600 mg, oral, every 24 hours, continued medication until the end of study.
Study NCT01856257 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mycophenolate mofetil
Description: Mycophenolate Mofetil will be administered at a target dose of 1000 mg orally twice a day. Myfortic® (mycophenolate sodium) may be used as a replacement for MMF. Mycophenolate sodium will be dosed at 720 mg PO BID. Mycophenolate sodium will be adjusted based on clinical complications.
Study NCT01856257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus
Description: The site investigator will identify a starting tacrolimus dose at their discretion, in order to achieve the target trough levels, no later than 5 days post-transplantation. The dose will be adjusted to 5-8ng/ml for the active comparator arm (thymoglobulin + tacrolimus + MMF arm) or tapered off in the experimental arm (basiliximab + 20 weeks of tacrolimus + MMF + belatacept).
Study NCT01856257 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tacrolimus
Description: The site investigator will identify a starting tacrolimus dose at their discretion, in order to achieve the target trough levels, no later than 5 days post-transplantation. The dose will be adjusted to 5-8ng/ml for the active comparator arm (thymoglobulin + tacrolimus + MMF arm) or tapered off in the experimental arm (basiliximab + 20 weeks of tacrolimus + MMF + belatacept).
Study NCT01102972 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Reyataz + Norvir + Truvada
Description: atazanavir 300mg + ritonavir 100mg + tenofovir 300mg/emtricitabine 200mg
Study NCT01102972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reyataz + Epzicom
Description: atazanavir 400mg + abacavir 600mg/lamivudine 300mg
Study NCT00850382 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Induction cycle(s):~Dasatinib 100 mg QD on days 8-21.~Consolidation Cycles 1, 2, 3, 4:~Patients will receive dasatinib 100 mg QD on days 6-28.~Maintenance therapy:~Patients completing consolidation therapy will continue to receive single agent dasatinib 100 mg QD for one year (or until relapse).
Study NCT01767116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-450/r/ABT-267, ABT-333
Description: Tablet; ABT-450 coformulated with ritonavir and ABT-267, ABT-333 tablet
Study NCT01767116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Capsule
Study NCT01767116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for ribavirin
Description: Capsule
Study NCT04289753 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EHR clinical decision support nudges
Description: Clinical decision support nudges delivered within the EHR when conditions meet alert triggering criteria.
Study NCT04289753 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief clinician education
Description: Clinicians will be invited to view brief education material.
Study NCT04289753 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief clinician education
Description: Clinicians will be invited to view brief education material.
Study NCT02256475 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NBI-98854
Study NCT03102476 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Humalog
Description: Subcutaneous injection of Humalog and assessing Pharmacokinetics and Pharmacodynamics properties of Humalog under different environmental conditions
Study NCT04584567 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Doxycyclin
Description: daily (100mg)
Study NCT04584567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycyclin
Description: daily (100mg)
Study NCT03801135 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fibrinogen concentrate
Description: Haemocomplettan will be infused after plasma exchange procedure
Study NCT03801135 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fresh Frozen Plasma
Description: Fresh frozen plasma will be part of replacement fluid
Study NCT04364997 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine Succinate Sustained-Release Tablet , Duloxetine Hydrochloride Enteric-coated Capsule Placebo
Description: Desvenlafaxine Succinate Sustained-Release Tablet 50 mg+Duloxetine Hydrochloride Enteric-coated Capsule Placebo 60 mg orally once daily for 8 weeks.
Study NCT00663793 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acyline
Description: 300 mcg/kg
Study NCT04364997 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desvenlafaxine Succinate Sustained-Release Tablet Placebo, Duloxetine Hydrochloride Enteric-coated Capsule
Description: Desvenlafaxine Succinate Sustained-Release Tablet Placebo 50mg +Duloxetine Hydrochloride Enteric-coated Capsule 60mg orally once daily for 8 weeks,
Study NCT04364997 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine Hydrochloride Enteric-coated Capsule Placebo
Description: Duloxetine Hydrochloride Enteric-coated Capsule Placebo 30 mg orally once daily for 1 week after 8-weeks treatment.
Study NCT04364997 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duloxetine Hydrochloride Enteric-coated Capsule
Description: Duloxetine Hydrochloride Enteric-coated Capsule 30mg orally once daily for 1 week after 8-weeks treatment.
Study NCT00663793 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone
Description: 24 hours after acyline administration on Day 2 immediate release Testosterone (T) 300 mg po once (as a control), followed 24 hours later (Day 3) by external matrix fast release T 300 mg once, followed 24 hours later (Day 4) by external matrix slow release T 300 mg once, followed 96 hours later (Day 8) by immediate release T 600 mg, followed 24 hours later (Day 9) by external matrix fast release T 600 mg po once, followed 48 hours later (Day 11) by external matrix slow release T 600 mg once.
Study NCT01809626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zolpidem
Study NCT01809626 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03679260 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Carbohydrate restricted diet
Description: 20 grams total carbs/day
Study NCT00850382 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daunorubicin
Description: Induction cycle(s):~Daunorubicin 60 mg/m2/day administered on days 1 through 3
Study NCT00850382 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Induction cycle(s):~Cytarabine 200 mg/m2/day administered by continuous IV infusion daily for 7 days (days 1 through 7).~Consolidation cycles 1, 2, 3, 4:~Consolidation therapy consists of high-dose cytarabine 3 g/m2 (>60 years: 1 g/m2) q12h, d 1, 3, 5, administered intravenously over three hours.
Study NCT04035694 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Media Aware Sexual Health - High School
Description: Media Aware is an online media literacy and sexual health education program developed for high school students that addresses the influence of media on sexual behaviors explicitly using established message processing theory. The program consists of 4 self-paced modules each with two to three lessons. Broadly, the modules cover healthy and unhealthy relationships, sexually transmitted infections, consent, substance use, pregnancy, protection and contraception, and communication between adolescents and their partners, parents, or health providers. Users also learn media literacy skills including message deconstruction to help examine the truth behind media messages.
Study NCT01922635 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Valadation of the metrological properties of questionnaire of quality of life
Study NCT04203888 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Swedish Massage
Description: 60-minute Swedish Massage delivered in-home by a licensed massage therapist, 2 times per week with at least 48-hours between massage interventions.
Study NCT04203888 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Yoga
Description: 60-minute yoga session delivered in-home by a certified yoga instructor, 2 times per week with at least 48-hours between yoga interventions.Yoga sessions will be based on the yoga postures available in the appendix of the December 2005 Annals of Internal Medicine article, Comparing Yoga, Exercise, and a Self-Care Book for Chronic Low Back Pain (Sherman KJ et al., 2005).
Study NCT03112096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]THK-5351
Description: Imaging for evaluating the biodistribution, pharmacokinetics and safety of abnormal tau protein in the brain
Study NCT03679260 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-restricted diet
Description: Subject follows normal diet
Study NCT03679260 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phone counseling with dietitian
Description: Weekly calls with dietitian
Study NCT02316743 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levothyroxine supplementation
Description: T4 supplementation for heart failure patients with subclinical hypothyroidism.
Study NCT02501655 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: phase 1 - jet nebulizer
Description: Aerosol generators diethilene penta-acetic triamine technetium (99mTc-DTPA) with radioactivity of 1 millicuries (Noble et al., 2007) mixed with 0.9% saline solution with a total volume of 4 ml using jet nebulizer (NS - mark) and 8l/min of the oxygen
Study NCT02501655 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Phase 2- mesh nebulizer
Description: Aerosol generators diethilene penta-acetic triamine technetium (99mTc-DTPA) with radioactivity of 1 millicuries (Noble et al., 2007) mixed with 0.9% saline solution with a total volume of 2 ml using vibrating mesh inhaler with valved chamber adapter (Aerogen Solo with Ultra Adapter, Aerogen Ltd).
Study NCT01984619 — intervention group
Intervention type: DEVICE
Intervention: Cryotherapy for the utilization of wrinkle reduction (iovera)
Study NCT00663793 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Finasteride
Description: 1 mg PO once daily \[day -2 to day 12) 14 days total
Study NCT04302870 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine Hydrochloride Oral Solution
Description: Memantine hydrocholoride taken once daily
Study NCT04302870 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trazodone Hydrochloride oral solution
Description: Trazodone Hydrochloride taken once daily
Study NCT04302870 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral solution
Description: Placebo taken once daily
Study NCT04302870 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amantadine Hydrochloride Oral Solution
Description: Amantadine Hydrochloride taken once daily
Study NCT04390776 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06651600
Description: PF-06651600 100 milligrams (mg) will be provided as Tablets and Capsules.
Study NCT03664024 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab, 200 mg, Day 1 of each 21-day cycle (Q3W), intravenous infusion (IV), standard of care in most countries
Study NCT01792661 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced MyChart
Description: Subjects randomized into the MyChart receive an additional site on their MyChart containing 35 extra educational links specific to CKD, targetting care for stage 3b and stage 4 patients.
Study NCT03664024 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed, 500 mg/m\^2 infusion, standard of care, Q3W, IV
Study NCT03664024 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin AUC 5 mg/mL/min, IV infusion, Day 1 of each 21-day cycle for 4 cycles (Cycles 1 - 4). Investigator's choice of either cisplatin or carboplatin.
Study NCT03664024 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin, 75 mg/m\^2, IV infusion, Day 1 of each 21-day cycle for 4 cycles (Cycles 1 - 4). Investigator's choice of either cisplatin or carboplatin.
Study NCT01792661 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patient Navigator
Description: The Patient Navigator aids subjects in education of their CKD, timely scheduling of appointments, plus determining and overcoming barriers to their CKD health care. The Patient Navigator's job is not part of routine medical care.
Study NCT01792661 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MyChart
Description: Sign-up to MyChart is optional for Cleveland Clinic patients. Subjects enrolled into the study are signed-up for MyChart (if not already signed-up) during the consenting process.
Study NCT02133326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caldolor
Description: Subject will be given Caldolor by IV prior to surgery.
Study NCT02133326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ofirmev
Description: Subject will be given Ofirmev prior to surgery.
Study NCT04846049 — intervention group
Intervention type: OTHER
Intervention: Comprehensive Care
Description: 1. Comprehensive Geriatric Assessment (3 visits with a geriatrician alternating with 3 primary provider visits over 6 months)~2. Care Planning with Interdisciplinary Team~3. Care coordination~4. Co-management with Primary care~5. Social work needs assessment~6. Patient-centered telehealth using phone, home telehealth, patient portal, Video~7. Transportation provided for all visits~8. Referral to Geriatric primary care clinic and mental health per Veteran need~9. Goals of Care and Veteran preferences conversation~10. Educate primary care providers about HNHR population, home and community based services, collaboration
Study NCT02930434 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: cholecalciferol
Description: Administration of vitamin D3
Study NCT04846049 — intervention group
Intervention type: OTHER
Intervention: Standard Care
Description: No intervention or treatment will be provided.
Study NCT00403923 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Lactose in water
Study NCT00820183 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality Improvement plan for Hypertension Control
Description: Implementation of a plan of quality improvement addressed to health professionals in Primary Health Care Teams. It includes:~Specific training programme on how to diagnose hypertension , and measure blood pressure correctly To send feed back information to primary care health professionals about poorly controlled hypertensive patients An audit will be performed, every 6 months, to see the adhesion to the recommended clinical guidelines , and the information will be diffused among the participant primary health care professionals Each participant primary health care team will have a designated reference person, that will provide support on any doubts on the programme implementation
Study NCT04461431 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arthroscopic anatomical reconstruction of the posterolateral structure of the knee
Description: Arthroscopic anatomical reconstruction of the posterolateral structure of the knee for patients with injury of the posterolateral structure of the knee
Study NCT02682173 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MR Abdomen
Study NCT01888978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gem-OX
Study NCT01888978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gem-5FU
Study NCT01888978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gem-Tax
Study NCT01888978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modified FOLFOX-6
Study NCT01888978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ox-Tax
Study NCT01888978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI
Study NCT01888978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tax-Iri
Study NCT01491737 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: Participants will receive a loading dose of 840 milligrams (mg) as an intravenous infusion on Day 1 of first treatment cycle, followed by 420 mg on Day 1 or Day 2 of each subsequent 3-week cycle until disease progression or unacceptable toxicity.
Study NCT01491737 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Participants will receive a loading dose of 8 milligrams per kilogram (mg/kg) as an intravenous infusion on Day 1 or 2 of first treatment cycle, followed by 6 mg/kg on Day 1 or Day 2 of each subsequent treatment 3-week cycles until disease progression or unacceptable toxicity.
Study NCT01491737 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: Participants will receive a loading dose of 8 milligrams per kilogram (mg/kg) as an intravenous infusion on Day 1 or 2 of first treatment cycle, followed by 6 mg/kg on Day 1 or Day 2 of each subsequent treatment 3-week cycles until disease progression or unacceptable toxicity.
Study NCT01491737 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aromatase Inhibitor
Description: Participants will receive 1 mg anastrozole or 2.5 mg letrozole orally once daily.
Study NCT01491737 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aromatase Inhibitor
Description: Participants will receive 1 mg anastrozole or 2.5 mg letrozole orally once daily.
Study NCT01491737 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Induction Chemotherapy
Description: Participants receiving induction chemotherapy up to the first 18-24 weeks of the treatment period will receive a taxane (docetaxel every 3 weeks or paclitaxel weekly), administered in line with the respective pertuzumab and/or trastuzumab infusions at the investigator's discretion.
Study NCT01491737 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Induction Chemotherapy
Description: Participants receiving induction chemotherapy up to the first 18-24 weeks of the treatment period will receive a taxane (docetaxel every 3 weeks or paclitaxel weekly), administered in line with the respective pertuzumab and/or trastuzumab infusions at the investigator's discretion.
Study NCT04203758 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cereal products based on rye
Description: Participants will receive a fixed amount of rye based cereals products, corresponding to approx 650 kcal/day.
Study NCT04203758 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cereal products based on wheat
Description: Participants will receive a fixed amount of wheat based cereals products, corresponding to approx 650 kcal/day.